Core Viewpoint - Shanghai is positioned to enhance its global competitiveness in the health industry through a series of proposals focusing on the integration of medical services, insurance, and pharmaceuticals, addressing challenges such as aging population and regulatory frameworks [1][3]. Group 1: Medical and Pharmaceutical Industry Development - The biopharmaceutical industry in Shanghai is transitioning from a "follower" to a "leader" phase, but faces challenges such as disconnection between innovation and industry chains, and imbalances in supply and demand [1][3]. - The implementation of the new regulations for biomedical technology and the first version of the commercial health insurance innovative drug directory are critical for Shanghai to leverage its role as a pioneer in reform [1][4]. Group 2: Regulatory and Pricing Challenges - The current regulatory framework for biomedical technologies lacks specificity, leading to potential inefficiencies in resource allocation and regulatory processes [4][5]. - There is a need for clear pricing standards for biomedical technologies, as existing regulations do not provide detailed guidelines for cost and pricing mechanisms [5][6]. Group 3: Health Insurance and Payment Mechanisms - To address the high costs of innovative drugs, proposals include expanding commercial health insurance coverage and optimizing reimbursement levels for innovative drugs, particularly those developed in Shanghai [7][8]. - A new funding pool for innovative drugs is suggested to support local high-value clinical innovations that are not yet included in national insurance negotiations [8][9]. Group 4: AI and Digital Transformation in Drug Development - The pharmaceutical industry is experiencing a paradigm shift towards digitalization and AI integration, with major companies investing heavily in AI technologies to enhance drug development efficiency [10][11]. - The establishment of a centralized data platform for biomedical research is proposed to overcome data fragmentation and enhance collaboration across institutions, aiming to create a world-class biomedical database by 2030 [12][13].

"十五五"规划开局之年，上海站在建设具有全球影响力的科技创新中心和健康城市建设的新起点。在此 背景下，2月2日，中国人民政治协商会议上海市第十四届委员会第四次会议在上海开幕。 面对国家层面多层次医疗保障体系的顶层设计出台、生物医学新技术监管新政实施，以及"新质老龄 化"带来的结构性挑战，此次会议，上海市政协常委、复星国际联席CEO陈启宇以医疗、医保、医药"三 医协同"的系统思维递交多份提案，为上海在大健康产业领域构筑全球竞争优势建言献策。 陈启宇指出，当前上海生物医药产业发展正处于从"跟跑"向"并跑""领跑"跨越的关键阶段，但创新链与 产业链脱节、支付端与供给端错配、老龄化需求与服务供给失衡等仍待进一步破题。特别是在国务院 《生物医学新技术临床研究和临床转化应用管理条例》即将实施、国家医保局发布首版《商业健康保险 创新药品目录》的政策背景下，上海要充分发挥改革开放排头兵作用。 此次陈启宇提出的系列提案立足于上海作为生物医药产业高地、医疗保障改革先行区、深度老龄化超大 城市的三重定位，从临床转化体系、多层次支付保障、科学智能基础设施、产业创新生态等维度提出具 体建议。 打通生物医药前沿技术转化通道 当前，新一轮 ...